Latest Milestone Payments News

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Dynamic Metals has agreed to sell non-core gold assets within its Widgiemooltha Project to Corazon Mining for up to $3.5 million, including cash, shares, milestone payments, and a 1.5% gold royalty, while retaining lithium rights.

Corazon Mining has significantly expanded its Western Australian gold footprint by acquiring key tenements adjacent to the Chalice Gold Project, adding 170km2 of prospective ground and securing gold rights over underexplored corridors.

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

Arcadia Minerals is progressing financing talks for its Swanson Tantalum Project amid a tantalum price rally, while defining drill targets for its nickel and lithium projects in Namibia.

Firebird Metals has secured a Perth site and placed all major equipment orders for its Australian Demonstration Plant, backed by a A$2 million ARENA grant. Independent testing confirms ultra-high purity manganese sulphate production, reinforcing its technology's potential.

Titan Minerals has ramped up drilling at its Dynasty Gold Project, confirming extensions to mineralisation and advancing scoping studies ahead of a resource upgrade targeted for early 2027.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

Miramar Resources has doubled its gold Exploration Target at the Gidji JV near Kalgoorlie and completed its first drilling program at Chain Pool in over 60 years, while finalising the sale of Randalls Project and securing government grants to fund ongoing exploration.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Aurora Energy Metals progresses the Aurora Uranium Project with a major drill program imminent under Eagle Nuclear Energy, while broadening its Western Australian footprint with new exploration licences at Mukinbudin.